219 related articles for article (PubMed ID: 9370234)
1. p53 mutations versus EGF receptor expression in giant cell glioblastomas.
Peraud A; Watanabe K; Plate KH; Yonekawa Y; Kleihues P; Ohgaki H
J Neuropathol Exp Neurol; 1997 Nov; 56(11):1236-41. PubMed ID: 9370234
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas.
Watanabe K; Tachibana O; Sata K; Yonekawa Y; Kleihues P; Ohgaki H
Brain Pathol; 1996 Jul; 6(3):217-23; discussion 23-4. PubMed ID: 8864278
[TBL] [Abstract][Full Text] [Related]
3. Genetic profile of the giant cell glioblastoma.
Peraud A; Watanabe K; Schwechheimer K; Yonekawa Y; Kleihues P; Ohgaki H
Lab Invest; 1999 Feb; 79(2):123-9. PubMed ID: 10068201
[TBL] [Abstract][Full Text] [Related]
4. Necrogenesis and Fas/APO-1 (CD95) expression in primary (de novo) and secondary glioblastomas.
Tohma Y; Gratas C; Van Meir EG; Desbaillets I; Tenan M; Tachibana O; Kleihues P; Ohgaki H
J Neuropathol Exp Neurol; 1998 Mar; 57(3):239-45. PubMed ID: 9600216
[TBL] [Abstract][Full Text] [Related]
5. p53 mutation and epidermal growth factor receptor overexpression in glioblastoma.
Yoon KS; Lee MC; Kang SS; Kim JH; Jung S; Kim YJ; Lee JH; Ahn KY; Lee JS; Cheon JY
J Korean Med Sci; 2001 Aug; 16(4):481-8. PubMed ID: 11511795
[TBL] [Abstract][Full Text] [Related]
6. Pathways leading to glioblastoma multiforme: a molecular analysis of genetic alterations in 65 astrocytic tumors.
Lang FF; Miller DC; Koslow M; Newcomb EW
J Neurosurg; 1994 Sep; 81(3):427-36. PubMed ID: 8057151
[TBL] [Abstract][Full Text] [Related]
7. Analysis of p53 mutation and epidermal growth factor receptor amplification in recurrent gliomas with malignant progression.
Reifenberger J; Ring GU; Gies U; Cobbers L; Oberstrass J; An HX; Niederacher D; Wechsler W; Reifenberger G
J Neuropathol Exp Neurol; 1996 Jul; 55(7):822-31. PubMed ID: 8965097
[TBL] [Abstract][Full Text] [Related]
8. Molecular analysis of microdissected de novo glioblastomas and paired astrocytic tumors.
Cheng Y; Ng HK; Ding M; Zhang SF; Pang JC; Lo KW
J Neuropathol Exp Neurol; 1999 Feb; 58(2):120-8. PubMed ID: 10029095
[TBL] [Abstract][Full Text] [Related]
9. Primary and secondary glioblastomas: from concept to clinical diagnosis.
Kleihues P; Ohgaki H
Neuro Oncol; 1999 Jan; 1(1):44-51. PubMed ID: 11550301
[TBL] [Abstract][Full Text] [Related]
10. Glioblastoma multiforme in an Asian population: evidence for a distinct genetic pathway.
Das A; Tan WL; Teo J; Smith DR
J Neurooncol; 2002 Nov; 60(2):117-25. PubMed ID: 12635658
[TBL] [Abstract][Full Text] [Related]
11. Amplification and overexpression of MDM2 in primary (de novo) glioblastomas.
Biernat W; Kleihues P; Yonekawa Y; Ohgaki H
J Neuropathol Exp Neurol; 1997 Feb; 56(2):180-5. PubMed ID: 9034372
[TBL] [Abstract][Full Text] [Related]
12. PTEN (MMAC1) mutations are frequent in primary glioblastomas (de novo) but not in secondary glioblastomas.
Tohma Y; Gratas C; Biernat W; Peraud A; Fukuda M; Yonekawa Y; Kleihues P; Ohgaki H
J Neuropathol Exp Neurol; 1998 Jul; 57(7):684-9. PubMed ID: 9690672
[TBL] [Abstract][Full Text] [Related]
13. Determination of p53 mutations, EGFR overexpression, and loss of p16 expression in pediatric glioblastomas.
Sure U; Rüedi D; Tachibana O; Yonekawa Y; Ohgaki H; Kleihues P; Hegi ME
J Neuropathol Exp Neurol; 1997 Jul; 56(7):782-9. PubMed ID: 9210874
[TBL] [Abstract][Full Text] [Related]
14. Primary glioblastomas with and without EGFR amplification: relationship to genetic alterations and clinicopathological features.
Benito R; Gil-Benso R; Quilis V; Perez M; Gregori-Romero M; Roldan P; Gonzalez-Darder J; Cerdá-Nicolas M; Lopez-Gines C
Neuropathology; 2010 Aug; 30(4):392-400. PubMed ID: 20051017
[TBL] [Abstract][Full Text] [Related]
15. Concurrent EGFR amplification and TP-53 mutation in glioblastomas.
Gil-Benso R; Lopez-Gines C; Benito R; López-Guerrero JA; Callaghan RC; Pellín A; Roldán P; Cerdá-Nicolas M
Clin Neuropathol; 2007; 26(5):224-31. PubMed ID: 17907599
[TBL] [Abstract][Full Text] [Related]
16. [Study on the expression of epidermal growth factor receptor and p53 in astrocytic gliomas: evidence for a distinct genetic pathway].
Dong L; Pu PY; Wang H; Wang GX; Kang CS; Jiao DR
Zhonghua Bing Li Xue Za Zhi; 2006 Apr; 35(4):232-6. PubMed ID: 16776982
[TBL] [Abstract][Full Text] [Related]
17. Preferential inactivation of the p53 tumor suppressor pathway and lack of EGFR amplification distinguish de novo high grade pediatric astrocytomas from de novo adult astrocytomas.
Sung T; Miller DC; Hayes RL; Alonso M; Yee H; Newcomb EW
Brain Pathol; 2000 Apr; 10(2):249-59. PubMed ID: 10764044
[TBL] [Abstract][Full Text] [Related]
18. p53 protein and epidermal growth factor receptor expression in human astrocytomas.
Kordek R; Biernat W; Alwasiak J; Maculewicz R; Yanagihara R; Liberski PP
J Neurooncol; 1995 Oct; 26(1):11-6. PubMed ID: 8583240
[TBL] [Abstract][Full Text] [Related]
19. Genetic profile of gliosarcomas.
Reis RM; Könü-Lebleblicioglu D; Lopes JM; Kleihues P; Ohgaki H
Am J Pathol; 2000 Feb; 156(2):425-32. PubMed ID: 10666371
[TBL] [Abstract][Full Text] [Related]
20. Roles of the functional loss of p53 and other genes in astrocytoma tumorigenesis and progression.
Nozaki M; Tada M; Kobayashi H; Zhang CL; Sawamura Y; Abe H; Ishii N; Van Meir EG
Neuro Oncol; 1999 Apr; 1(2):124-37. PubMed ID: 11550308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
